Here is a list of the current clinical trials at Broward Health where we are actively enrolling patients. If you have any questions, please feel free to contact us.


  • Lung
    • FDI-213: A Prospective Collection of Peripheral Blood from Adults for CYFRA-21-1, SCC and NSE Assay Reference Range Determination
  • Breast
    • Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests
    • Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
    • SWOG S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study     
  • Gynecologic
    • GOG 3038: An Umbrella Study of INCMGA00012 Alone and in Combination with Other Therapies in Participants with Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)  
    • GOG-3083: A Phase III, Randomized Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (ENGOT) 
  • Head and Neck 
    • EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
    • The Efficacy of Topical Fibrin Sealant in the Reduction of Post-Operative Pain After Head and Neck Surgery
  •  Biospecimen Trials
    • The Utility of Molecular Diagnostics from Cervicovaginal Sampling in Endometrial Cancer  
    • University of Arizona - Supportive Care Research Studies After Cancer Treatment (Protocol# 1711069340R2002)
    • NSU and Broward Health Collaboration: Tissue Samples and Nucleotide Excision Repair Capacity to Evaluate the Nucleotide Excision Repair (NER) Capacity of Non-Tumor Adjacent (NTA) Tissue
    • SERATRIALS - 18004: A Multi-Center Study for the Collection of Biospeciments for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research 
    • MT Group: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (Specimen Trial)    
      • MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients



  • AIM HIGHer: Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction 
  • INTEGRA-D: Assessment of the Safety and Efficacy of Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects with Heart Failure and Reduced Ejection Fraction



  • AL002: Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer's Disease    
  • Post-Stroke Follow-Up Telephone Call for Discharge Plan of Care Compliance



  • Leukemia
    • AALL1631: A Children’s Oncology Protocol for an International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone   
    • AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) 
    • AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-risk B-ALL; Risk-Adapted Post-induction Therapy for High-risk B-ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy
  • Neuroblastoma
    • ANBL00B1: A Children’s Oncology Group Protocol for Biomarkers in Tumor Tissue Samples from Patients with Newly Diangosed Neuroblastoma or Ganglioneuroblastoma
    • ANBL1232: Utilizing Response- and Biology- Based Risk FActors to Guide Therapy in Patients With Non-High Risk Neuroblastoma
  • Renal/Kidney
    • AREN03B2: A Children’s Oncology Group Protocol for Study of Kidney Tumors in Younger Patient 
  • Other
    • ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
    • APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
    • AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors 
    • APEC14B1: A Children’s Oncology Protocol for Project: EveryChild: A Registry, Eligibility Screening, Biology, and Outcome Study
    • ACCL20N1CD: Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
    • ALTE1631: A Randomized Web-Based Physicial Activity Intervention Among Children and Adolescents With Cancer
    • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
    • AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and A Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    • ARTES2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, nad Cyclophosphamide (VINO-AC) vs. Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
    • ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC#748726 IND#125462) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
    • APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
    • ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low Risk and Low Risk Negative Rhabdomyosarcoma